Association Between Metabolic Syndrome and the Risk of Lung Cancer: A Meta-Analysis

Abstract

Previous studies showed conflicting results regarding the association between metabolic syndrome (MetS) and risk of lung cancer. We performed a systemic review and meta-analysis to determine the relationship between MetS and lung cancer incidence and mortality in adults. Longitudinal follow-up studies were identified by search of Medline, Embase, Cochrane Library, and Web of Science. By incorporating potential heterogeneity into the model, a randomized-effects model was selected to pool the results. Fourteen observational studies were included. Pooled results showed that MetS was associated with a higher risk of lung cancer incidence [risk ratio (RR): 1.15, 95% confidence interval (CI): 1.05 to 1.26, p=0.002; I²=89%). Subgroup analysis suggested that the association was not significantly affected by study country, design, sex of the participants, adjustment of smoking, or different study quality scores (p for subgroup difference all>0.05). The association was predominantly contributed by studies with MetS defined by the National Cholesterol Education Program Adult Treatment Panel-III rather than those with MetS defined by the International Diabetes Foundation criteria, and the association seemed to be stronger in studies with follow-up within 6 years than those over 6 years (p for subgroup difference=0.03 and 0.04, respectively). In addition, pooled results also showed that MetS was associated with a higher risk of lung cancer mortality (RR: 1.46, 95% CI: 1.19 to 1.79, p <0.001; I²=0%). In conclusion, in adult population, MetS may be a risk factor of lung cancer incidence and mortality.

Key words

metabolic syndrome - lung cancer - incidence - mortality - meta-analysis

Publication History

Received: 07 July 2023

Accepted after revision: 11 September 2023

Article published online:
02 November 2023

• References

• 1 Siegel RL, Miller KD, Wagle NS. et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48
• 2 Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol 2021; 33: 40-46
• 3 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249
• 4 Alduais Y, Zhang H, Fan F. et al. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 2023; 102: e32899
• 5 Megyesfalvi Z, Gay CM, Popper H. et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 2023;
• 6 Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019; 28: 1563-1579
• 7 Oliver AL. Lung cancer: epidemiology and screening. Surg Clin North Am 2022; 102: 335-344
• 8 Vedire Y, Kalvapudi S, Yendamuri S. Obesity and lung cancer-a narrative review. J Thorac Dis 2023; 15: 2806-2823
• 9 Lee JY, Jeon I, Lee JM. et al. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer 2013; 49: 2411-2423
• 10 Merino Salvador M, Gomez de Cedron M, Moreno Rubio J. et al. Lipid metabolism and lung cancer. Crit Rev Oncol Hematol 2017; 112: 31-40
• 11 Ahmed M, Kumari N, Mirgani Z. et al. Metabolic syndrome; definition, pathogenesis, elements, and the effects of medicinal plants on it’s elements. J Diabetes Metab Disord 2022; 21: 1011-1022
• 12 Ambroselli D, Masciulli F, Romano E. et al. New advances in metabolic syndrome, from prevention to treatment: the role of diet and food. Nutrients 2023; 15: 640
• 13 Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20: 12
• 14 Fahed G, Aoun L, Bou Zerdan M. et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci 2022; 23: 786
• 15 Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. Curr Opin Urol 2022; 32: 594-597
• 16 Esposito K, Chiodini P, Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
• 17 Qiao L, Ma D, Lv H. et al. Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies. Diabetol Metab Syndr 2020; 12: 95
• 18 Watanabe J, Kakehi E, Kotani K. et al. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr 2019; 11: 3
• 19 Sin S, Lee CH, Choi SM. et al. Metabolic syndrome and risk of lung cancer: an analysis of Korean national health insurance corporation database. J Clin Endocrinol Metab 2020; 105: dgaa596
• 20 Choe JW, Hyun JJ, Kim B. et al. Influence of metabolic syndrome on cancer risk in HBV carriers: a nationwide population based study using the National Health Insurance Service Database. J Clin Med 2021; 10: 2401
• 21 Li L, Meng F, Xu D. et al. Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested case-control study based on the China Health and Retirement Longitudinal Study (CHARLS). BMJ Open 2022; 12: e061362
• 22 Lopez T, Duarte-Salles T, Plana-Ripoll O. et al. Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study. PLoS One 2022; 17: e0264634
• 23 Shao F, Chen Y, Xu H. et al. Metabolic obesity phenotypes and risk of lung cancer: a prospective cohort study of 450,482 UK biobank participants. Nutrients 2022; 14: 3370
• 24 Van Hoang D, Inoue Y, Fukunaga A. et al. Metabolic syndrome and the risk of severe cancer events: a longitudinal study in Japanese workers. BMC Cancer 2023; 23: 555
• 25 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
• 26 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
• 27 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 28 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
• 29 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 30 Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer 2008; 44: 293-297
• 31 Inoue M, Noda M, Kurahashi N. et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009; 18: 240-247
• 32 Jaggers JR, Sui X, Hooker SP. et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009; 45: 1831-1838
• 33 Osaki Y, Taniguchi S, Tahara A. et al. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012; 36: 141-147
• 34 van Kruijsdijk RC, van der Graaf Y, Peeters PH. et al. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Cancer Epidemiol Biomarkers Prev 2013; 22: 1267-1277
• 35 Ko S, Yoon SJ, Kim D. et al. Metabolic risk profile and cancer in Korean men and women. J Prev Med Public Health 2016; 49: 143-152
• 36 Gathirua WG, Monahan PO, Murage MJ. et al. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control 2017; 28: 127-136
• 37 Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA 2020; 323: 2526-2528
• 38 Khusnurrokhman G, Wati FF. Tumor-promoting inflammation in lung cancer: a literature review. Ann Med Surg (Lond) 2022; 79: 104022
• 39 Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift. Diab Vasc Dis Res 2019; 16: 118-127
• 40 Argirion I, Weinstein SJ, Mannisto S. et al. Serum insulin, glucose, indices of insulin resistance, and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2017; 26: 1519-1524
• 41 Hidayat K, Du X, Chen G. et al. Abdominal obesity and lung cancer risk: systematic review and meta-analysis of prospective studies. Nutrients 2016; 8: 810
• 42 Lin X, Lu L, Liu L. et al. Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies. J Clin Lipidol 2017; 11: 1073-1081
• 43 Wei X, Zhu C, Ji M. et al. Diet and risk of incident lung cancer: a large prospective cohort study in UK biobank. Am J Clin Nutr 2021; 114: 2043-2051
• 44 Murphy RA, Darvishian M, Qi J. et al. Lifestyle factors and lung cancer risk among never smokers in the Canadian Partnership for Tomorrow’s Health (CanPath). Cancer Causes Control 2022; 33: 913-918